No. 12 / 2025 Zealand Pharma announces closing of collaboration and license agreement with Roche Copenhagen, Denmark, May 9, ...

Zealand Pharma AS (ZLDPF) reports robust financials and transformative partnerships, setting the stage for future growth in ...

Zealand Pharma Announces Financial Results for the First Three Months of 2025 Significant progress in the clinical pipeline, ...

Zealand Pharma A/S (($DK:ZEAL)) has held its Q1 earnings call. Read on for the main highlights of the call. Zealand Pharma’s recent earnings call ...

Petrelintide/CT-388, amylin+GLP-1/GIP fixed-dose combination. Zealand Pharma and Roche expect to initiate Phase 2 trials with petrelintide/CT-388 in the first half of 2026. Dapiglutide ...

“Zealand Pharma has never been in a stronger position than we are ... The strong foundation enables us to unlock the full value potential of petrelintide in partnership with Roche and significantly ...

Zealand Pharma reported Q1 2025 revenue of 8 million DKK. A transformative collaboration with Roche is expected to bring a $1.4 billion upfront payment. The company is strengthening its obesity ...

Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.